Cortical abnormalities of synaptic vesicle protein 2A in focal cortical dysplasia type II identified in vivo with 18F-SynVesT-1 positron emission tomography imaging

[1]  Yiyun Huang,et al.  Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  B. Tang,et al.  FDG-PET Profiles of Extratemporal Metabolism as a Predictor of Surgical Failure in Temporal Lobe Epilepsy , 2020, Frontiers in Medicine.

[3]  D. Spencer,et al.  Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography study , 2020, Epilepsia.

[4]  Richard E Carson,et al.  Assessment of a white matter reference region for 11C-UCB-J PET quantification , 2020, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  Yiyun Huang,et al.  First-in-Human Evaluation of 18F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A , 2020, The Journal of Nuclear Medicine.

[6]  M. Zhou,et al.  An SV2A-Specific Radioligand 18F-SDM-8 for the Evaluation of FCD Foci , 2020 .

[7]  A. Luxen,et al.  Exploring with [18F]UCB-H the in vivo Variations in SV2A Expression through the Kainic Acid Rat Model of Temporal Lobe Epilepsy , 2020, Molecular Imaging and Biology.

[8]  Yiyun Huang,et al.  Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging , 2020, Annals of neurology.

[9]  R. Hill,et al.  Myelin plasticity in adulthood and aging , 2019, Neuroscience Letters.

[10]  M. Panigrahi,et al.  Focal Cortical Dysplasia and Refractory Epilepsy: Role of Multimodality Imaging and Outcome of Surgery , 2019, American Journal of Neuroradiology.

[11]  Dustin Scheinost,et al.  Lower synaptic density is associated with depression severity and network alterations , 2019, Nature Communications.

[12]  Yiyun Huang,et al.  Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates. , 2018, ACS chemical neuroscience.

[13]  Richard E Carson,et al.  Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging , 2018, JAMA neurology.

[14]  B. Devaux,et al.  18F-FDG PET in drug-resistant epilepsy due to focal cortical dysplasia type 2: additional value of electroclinical data and coregistration with MRI , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  Yanyao Yi,et al.  Sample size calculations in clinical research, third edition, by Shein-Chung Chow, Jun Shao, Hansheng Wang, and Yuliya Lokhnygina , 2017 .

[16]  Kai Zhang,et al.  Glucose Metabolic Profile by Visual Assessment Combined with Statistical Parametric Mapping Analysis in Pediatric Patients with Epilepsy , 2017, The Journal of Nuclear Medicine.

[17]  Jeffrey A. Stanley,et al.  Adult age differences in subcortical myelin content are consistent with protracted myelination and unrelated to diffusion tensor imaging indices , 2016, NeuroImage.

[18]  J. Salzer,et al.  Myelination , 2016, Current Biology.

[19]  B. Stevens,et al.  New insights on the role of microglia in synaptic pruning in health and disease , 2016, Current Opinion in Neurobiology.

[20]  Pavel Krsek,et al.  Diagnostic methods and treatment options for focal cortical dysplasia , 2015, Epilepsia.

[21]  Z. Qiu,et al.  Coordinated Spine Pruning and Maturation Mediated by Inter-Spine Competition for Cadherin/Catenin Complexes , 2015, Cell.

[22]  América Vanoye-Carlo,et al.  Synaptic vesicle protein 2A: basic facts and role in synaptic function , 2013, The European journal of neuroscience.

[23]  Terence J O'Brien,et al.  18F-Flumazenil: A γ-Aminobutyric Acid A–Specific PET Radiotracer for the Localization of Drug-Resistant Temporal Lobe Epilepsy , 2013, The Journal of Nuclear Medicine.

[24]  K. Kurisu,et al.  Low distribution of synaptic vesicle protein 2A and synaptotagimin-1 in the cerebral cortex and hippocampus of spontaneously epileptic rats exhibiting both tonic convulsion and absence seizure , 2012, Neuroscience.

[25]  Maria Thom,et al.  The clinicopathologic spectrum of focal cortical dysplasias: A consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission 1 , 2011, Epilepsia.

[26]  P. Merlet,et al.  FDG-PET improves surgical outcome in negative MRI Taylor-type focal cortical dysplasias , 2010, Neurology.

[27]  Koen Van Laere,et al.  EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  Maria Thom,et al.  Focal cortical dysplasia type II: biological features and clinical perspectives , 2009, The Lancet Neurology.

[29]  J. Reijneveld,et al.  Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC‐cortical tubers , 2009, Epilepsia.

[30]  E. Aronica,et al.  Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy , 2009, Epilepsia.

[31]  T. Bast,et al.  Focal cortical dysplasia: prevalence, clinical presentation and epilepsy in children and adults , 2006, Acta neurologica Scandinavica.

[32]  P. Bacchetti,et al.  Sample size calculations in clinical research. , 2002, Anesthesiology.

[33]  Brian D. Hale,et al.  Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  William D. Gaillard,et al.  The effect of vigabatrin (γ-vinyl GABA) on cerebral blood flow and metabolism , 1999 .

[35]  M. Feany,et al.  The synaptic vesicle protein SV2 is a novel type of transmembrane transporter , 1992, Cell.

[36]  R. Scheller,et al.  SV2, a brain synaptic vesicle protein homologous to bacterial transporters. , 1992, Science.

[37]  W H Theodore,et al.  Antiepileptic Drugs and Cerebral Glucose Metabolism , 1988, Epilepsia.

[38]  M. Carpenter.  Myelination , 1972, Neurology.

[39]  W H Theodore,et al.  The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. , 1999, Neurology.